The FDA today published a request for medical device company Allergan to recall its textured breast implant products after data linked the products to an increased risk for cancer.
The company’s website also has been updated with an announcement of its global recall in response to the FDA’s updated safety information on the product.
Since 2011 the FDA has been monitoring databases after the association between anaplastic large cell lymphoma (ALCL) and certain breast implants was suspected. So far, 573 cases of breast-implant associated (BIA) ALCL, and 33 patient deaths, have been identified, and a large number are related to Allergan’s textured implants.
Allergan’s recall includes BIOCELL® textured breast implants and tissue expanders, a product line which includes dozens of separate breast implant items.
Today’s news comes after recent announcements from Australia and Canada that the countries were implementing bans on textured breast implants as well. In 2017, a study published in the Journal of the American Society of Plastic Surgeons documented the increased risk of BIA-ALCL, and agencies the world over have closely monitored reports of the disease since.
If you or a loved one has suffered cancer, specifically breast-implant associated anaplastic large cell lymphoma (BIA-ALCL), you may have a legal claim against the manufacturers of the breast implants. Contact an attorney at Egerton Law to discuss your potential claim today.